Disease and Treatment-Specific Complications of Behçet Syndrome

被引:2
作者
Esatoglu, Sinem Nihal [1 ,2 ]
Ozguler, Yesim [1 ,2 ]
Hatemi, Gulen [1 ,2 ]
机构
[1] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Internal Med, Div Rheumatol, Istanbul, Turkiye
[2] Istanbul Univ Cerrahpasa, Behcets Dis Ctr, Istanbul, Turkiye
关键词
Behcet syndrome; Vasculitis; Complications; Treatment; Side effects; Damage;
D O I
10.1007/s11926-023-01124-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of ReviewWe aimed to highlight disease-related and treatment-related complications of Behcet syndrome (BS) based on previous and recent studies and our own experience.Recent FindingsThe Behcet's Disease Overall Damage Index is a newly developed instrument to assess damage in BS. Validation studies showed that damage is already present in some patients at diagnosis and continues to progress during the follow-up, mainly related to treatment complications. Nervous system and eye involvement are important causes of long-term disability. Cyclophosphamide seems to be associated with infertility and an increased risk of malignancies among BS patients, prompting the consideration of shortening the treatment duration. Flares in mucocutaneous manifestations have been reported with tocilizumab, and de novo BS manifestations with secukinumab therapy.SummaryEarlier diagnosis and treatment are essential to prevent disease-related damage in BS. Treatment-related complications seem to be the leading cause of damage during the disease course.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 102 条
[1]   Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behcet's disease [J].
Adler, YD ;
Mansmann, U ;
Zouboulis, CC .
DERMATOLOGY, 2001, 203 (04) :322-324
[2]   IFN-α Mediates the Development of Autoimmunity both by Direct Tissue Toxicity and through Immune Cell Recruitment Mechanisms [J].
Akeno, Nagako ;
Smith, Eric P. ;
Stefan, Mihaela ;
Huber, Amanda K. ;
Zhang, Weijia ;
Keddache, Mehdi ;
Tomer, Yaron .
JOURNAL OF IMMUNOLOGY, 2011, 186 (08) :4693-4706
[3]   Effectiveness of tocilizumab in Behcet's disease: A systematic literature review [J].
Akiyama, Mitsuhiro ;
Kaneko, Yuko ;
Takeuchi, Tsutomu .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (04) :797-804
[4]  
Akman-Demir G, 2008, CLIN EXP RHEUMATOL, V26, pS84
[5]   Clinical patterns of neurological involvement in Behcet's disease:: evaluation of 200 patients [J].
Akman-Demir, G ;
Serdaroglu, P ;
Tasçi, B .
BRAIN, 1999, 122 :2171-2181
[6]   Predictors for the risk and severity of post-thrombotic syndrome in vascular Behcet's disease [J].
Aksoy, Aysun ;
Colak, Seda ;
Yagiz, Burcu ;
Coskun, Belkis Nihan ;
Omma, Ahmet ;
Yildiz, Yasin ;
Sari, Alper ;
Atas, Nuh ;
Ilgin, Can ;
Karadag, Omer ;
Erden, Abdulsamet ;
Dalkilic, Ediz ;
Bolca, Naile ;
Ergelen, Rabia ;
Onur, Mehmet Ruhi ;
Direskeneli, Haner ;
Alibaz-Oner, Fatma .
JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS, 2021, 9 (06) :1451-1459
[7]  
Alder NM, 2008, CLIN EXP RHEUMATOL, V26, pS110
[8]   Interferon alfa-2a in the treatment of Behcet disease - A randomized placebo-controlled and double-blind study [J].
Alpsoy, E ;
Durusoy, C ;
Yilmaz, E ;
Ozgurel, Y ;
Ermis, O ;
Yazar, S ;
Basaran, E .
ARCHIVES OF DERMATOLOGY, 2002, 138 (04) :467-471
[9]  
[Anonymous], 1999, Neurology, V53, P457
[10]   Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders [J].
Arnold, Dennis D. ;
Yalamanoglu, Ayla ;
Boyman, Onur .
FRONTIERS IN IMMUNOLOGY, 2022, 13